1110641-96-7

Basic information

• Product Name: (S)-6-allyl-3-((R)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one
• Synonyms: (S)-6-allyl-3-((R)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one
• CAS NO: 1110641-96-7
• Molecular Weight: 418.306
• Mol File: 1110641-96-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-6-allyl-3-((R)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-allyl-3-((R)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one(1110641-96-7)
• EPA Substance Registry System: (S)-6-allyl-3-((R)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one(1110641-96-7)

Safety Data

• Hazardous Substances Data: 1110641-96-7(Hazardous Substances Data)

Upstream product

• 1110641-72-9 1-chloro-3-(4-fluorophenyl)hex-5-en-3-ol 
• 618461-78-2 (R)-1-(4-bromophenyl)ethyl isocyanate 

Relevant articles and documents

SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

Disclosed are syntheses of 11 beta-HSD1 inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes, metabolic syndrome, obesity, glucose intolerance, insulin resistance, hyperglycemia, hypertension, hypertension-related cardiovascular disorders, hyperlipidemia, deleterious gluco-corticold effects on neuronal function (e.g. cognitive impairment, dementia, and/or depression), elevated intra-ocular pressure, various forms of bone disease (e.g., osteoporosis), tuberculosis, leprosy (Hansen's disease), psoriasis, and impaired wound healing (e.g., in patients that exhibit impaired glucose tolerance and/or type 2 diabetes).